Can-Fite BioPharma Ltd.

CANF | AMEX

Price Alert Chart Builder DCF Calculator

$2.22

-$0.02 (-0.89%)

At close: Sep 21, 2026, 4:00 PM ET

$2.26

+$0.04 (+1.74%)

Pre-market: Sep 22, 2026, 4:44 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.89%

(1D)

Rating

Updated: Aug 28, 2026

25.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.91M

1D Range

2.22 2.28

52W Range

2.16 12.80

Valuation (TTM)

PE -2.47

PB 0.69

EV/EBITDA 0.39

Valuation (NTM)

Forward PE 2.75

Forward PEG 0.01

Price Target $8

Cash Flow

FCF Yield -287.5%

SBC Adj. FCF Yield -301.9%

SBC Impact -5.0%

Margins

Gross Margin 100.0%

Operating Margin -1595.4%

FCF Margin -1492.0%

Growth (CAGR)

Revenue 3Y | 5Y -13.5% | -20.3%

Dil EPS 3Y | 5Y 61.3% | 45.8%

FCF 3Y | 5Y -104.9% | -86.5%

Returns

ROA -118.6%

ROE -182.9%

ROIC -165.6%

Financial Health

Net Cash

$6.46M

Current Ratio 3.60

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions includin...

Sector Healthcare

Industry Biotechnology

Employees 5

IPO Date Nov 5, 2012

Website www.canfite.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Sep 8, 2026

EPS

-$0.33

Miss 0.00%

YoY: -23471.43%

REV

$202K

Miss -32.67%

YoY: 0.00%

Next Earnings

Apr 1, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+260.36%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞